Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement
Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry
Ultimovacs Cancer Vaccine Faces Significant Challenges After Third Consecutive Failure
Ultimovacs, cancer vaccine, phase 2 trial, clinical failure, financial struggles, biotechnology
Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology
Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders
Bayer’s Transformation Accelerates with 3,200 Job Cuts in 2024
Bayer, transformation, job cuts, 2024, Bill Anderson, pharmaceutical industry
Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million
Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring